The UK’s National Biologics Manufacturing Centre will use Novasep’s BioSC Lab for protein purification.
The Centre for Process Innovation (CPI), a UK-based technology innovation center that provides services to small and medium-sized enterprises in the UK, has equipped the UK National Biologics Manufacturing Centre with Novasep’s BioSC Lab for protein purification. CPI’s services are intended to decrease time to market for novel products or processes. Within this framework, the CPI has been keen to introduce breakthrough continuous processes in the UK biopharmaceutical sector, CPI said in a press release. These technologies enable developers to reduce equipment footprint and increase process yields, thereby saving time and money.
“The National Biologics Manufacturing Centre has been designed to help companies of all sizes to develop, prove, and commercialize new and improved processes and technologies for biopharmaceutical manufacture,” said Chris Dowle, director of biologics at CPI, in the release. “The installation of Novasep’s BioSC Lab will be a valuable asset to customers using the centre."
Novasep’s continuous biochromatography equipment, BiosSC Lab, can purify a few grams of proteins per day. This enables users to develop cost-effective, high-yield production processes while maintaining the same quality attributes of the protein. The equipment is flexible and supports any process operating mode, including batch, parallel batch, and continuous. It is specifically designed to quickly provide the operator with the best operational parameters for purifying and converting a batch biochromatography recipe into a continuous, optimized one. Its simulation software, BioSC Predict, frees the process developer to set the most efficient mode and parameters to purify biomolecules such as monoclonal antibodies (mAbs), blood factors, and other proteins.
Source: Novasep
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Legal and Regulatory Perspectives on 3D Printing: Drug Compounding Applications
December 10th 2024This paper explores the legal and regulatory framework around 3D drug printing, particularly for personalized medicine, considering regulatory compliance, business concerns, and intellectual property rights.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.